0001209191-21-017527.txt : 20210303 0001209191-21-017527.hdr.sgml : 20210303 20210303203447 ACCESSION NUMBER: 0001209191-21-017527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leen Ann M. CENTRAL INDEX KEY: 0001763026 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 21712066 MAIL ADDRESS: STREET 1: 5 WEST FORSYTH STREET STREET 2: SUITE 200 CITY: JACKSONVILLE STATE: FL ZIP: 32202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001754068 Allovir, Inc. ALVR 0001763026 Leen Ann M. C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2021-03-01 4 S 0 6359 38.4607 D 2465326 I See Footnote Common Stock 2021-03-01 4 S 0 3159 39.1762 D 2462167 I See Footnote Common Stock 28000 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.89 to $38.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. /s/ Brett Hagen, as Attorney-in-Fact 2021-03-03